New findings from the J&J prostate cancer drug study presented at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting suggest that adding apalutamide (marketed as Erleada) to standard hormone therapy before and after prostate surgery may significantly improve outcomes for men with high-risk prostate cancer.
The results come from the Phase III PROTEUS trial by Johnson & Johnson, one of the largest studies ever conducted in this patient population. Researchers reported that the treatment combination reduced the risk of disease progression, recurrence, or death while improving the chances of achieving minimal or no detectable cancer at the time of surgery.
The findings, simultaneously published in the New England Journal of Medicine and presented during ASCO 2026, are being described by experts as potentially practice-changing for patients with localized and locally advanced disease.
What Does The J&J Prostate Cancer Drug Study Show?
The PROTEUS trial results evaluated more than 2,000 men with high-risk localized or locally advanced prostate cancer who were eligible for radical prostatectomy, the surgery that removes the prostate gland.
Participants received either:
- Apalutamide (Erleada) plus androgen deprivation therapy (ADT), or
- Placebo plus ADT
The J&J prostate cancer drug treatment was given both before surgery (neoadjuvant therapy) and after surgery (adjuvant therapy) to the patients.
According to data presented at ASCO 2026, 8.9% of patients receiving apalutamide plus ADT had little or no detectable cancer remaining at surgery, compared with only 1% of patients receiving hormone therapy alone.
Researchers also found that the combination therapy reduced the risk of cancer spread or death by 20%. Patients receiving extended prostate cancer treatment experienced nearly twice as long before needing additional therapy compared with those receiving standard hormone treatment alone.
Many specialists believe this could become a new standard treatment approach for patients facing aggressive prostate cancer.
Dr. Mary-Ellen Taplin of Dana-Farber Cancer Institute, the study’s lead investigator, described the findings as “paradigm changing,” noting that no androgen receptor pathway inhibitors are currently approved for localized high-risk prostate cancer in combination with surgery.
How J&J Drug Erleada Works Against Prostate Cancer
The new J&J locally advanced prostate cancer treatment approach centers on apalutamide, a medication that blocks signals from male hormones that fuel prostate cancer growth.
Apalutamide belongs to a class of medicines known as androgen receptor pathway inhibitors. These drugs prevent cancer cells from receiving hormonal signals that encourage tumor growth and spread.
According to investigators, using the drug both before and after surgery may help reduce tumor burden, improve long-term disease control, and delay future treatment needs.
The J&J prostate cancer drug study addresses a major unmet need. Nearly half of patients treated with surgery and radiation eventually experience disease recurrence and require additional treatment.
J&J Phase III Prostate Cancer Trial Could Influence Future Guidelines
The Phase III prostate cancer trial results may have significant implications for treatment guidelines worldwide.
Johnson & Johnson has announced plans to work with regulators to pursue expanded approvals for Erleada in earlier stages of prostate cancer. If approved, the therapy could offer physicians another option for managing patients with aggressive disease before cancer spreads.
Importantly, researchers of the J&J prostate cancer drug study reported that the safety profile remained consistent with previous studies. Common side effects included hot flashes, urinary incontinence, and erectile dysfunction, which are already known risks associated with hormone-based prostate cancer treatments.
Conclusion
The prostate cancer study presented at ASCO 2026 by Johnson & Johnson provides encouraging evidence that a combination of hormone therapies before and after surgery may improve outcomes for men with high-risk prostate cancer.
While regulatory review is still pending, the results suggest that integrating apalutamide into perioperative care could help reduce recurrence, delay disease progression, and improve long-term survival. As additional analyses emerge, the PROTEUS trial may become one of the most influential studies shaping future prostate cancer treatment strategies.
